Insider Buying: Sareum Holdings plc (LON:SAR) Insider Purchases 84,033 Shares of Stock

Sareum Holdings plc (LON:SAR) insider Stephen Parker acquired 84,033 shares of the stock in a transaction dated Wednesday, March 26th. The stock was bought at an average price of GBX 12 ($0.16) per share, for a total transaction of £10,083.96 ($13,051.98).

Sareum Stock Performance

Shares of SAR opened at GBX 13.44 ($0.17) on Friday. The firm has a market capitalization of £16.79 million, a P/E ratio of -3.18 and a beta of -1.08. Sareum Holdings plc has a 52 week low of GBX 10.03 ($0.13) and a 52 week high of GBX 52.50 ($0.68). The company has a 50-day simple moving average of GBX 17.47 and a 200-day simple moving average of GBX 23.

Sareum (LON:SAR) last announced its quarterly earnings results on Tuesday, March 25th. The company reported GBX (0.90) (($0.01)) earnings per share for the quarter. As a group, equities analysts forecast that Sareum Holdings plc will post -3.8 earnings per share for the current year.

About Sareum

Sareum is a specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases. The Company aims to generate value through licensing its candidates to international pharmaceutical and biotechnology companies at the preclinical or early clinical trials stage.
Sareum is advancing internal programmes focused on distinct dual tyrosine kinase 2 (TYK2) / Janus kinase 1 (JAK1) inhibitors through preclinical development as therapies for autoimmune diseases, including the ‘cytokine storm’ immune system overreaction to Covid-19 and other viral infections, (SDC-1801) and cancer immunotherapy (SDC-1802).
Sareum also has an economic interest in SRA737, a clinical-stage oral, selective Checkpoint kinase 1 (Chk1) inhibitor that targets cancer cell replication and DNA damage repair mechanisms.